Suchergebnisse
Suchergebnisse:
View Jerry McMahon’s profile on LinkedIn, a professional community of 1 billion members. Dr. McMahon brings more than 30 years of exceptional biotechnology leadership, scientific…
- 500+
- 1.2K
- Jerry Mcmahon
- San Francisco, California, United States
Jerry McMahon, PhD Chief Executive Officer & President Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience.
7. Sept. 2022 · Dr. Jerry McMahon added: “STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME. STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first ...
7. Sept. 2022 · 7 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board ...
7. Sept. 2022 · STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer. Sep 07, 2022, 03:00 ET. Industry veteran to lead STORM as it transitions into a clinical-stage company with a pipeline...
23. Nov. 2022 · Dr Jerry McMahon, CEO of STORM Therapeutics, said: “This is a major milestone for STORM as we enter clinical development with our lead candidate STC-15 and continue progressing a pipeline targeting RNA modifying enzymes beyond METTL3.
Dr Jerry McMahon has been appointed CEO for STORM Therapeutics as it transitions into a clinical-stage company with a pipeline of products targeting RNA modifying enzymes. STORM Therapeutics is a biotechnology company specialising in discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and ...
